A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 173 participants.
Also called NCT04896008
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 173 participants
- Registry
-
NCT04896008 -
2023-509140-10-00 -
U1111-1309-6376 -
2021-001498-21
-
- Other papers using this trial's data
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Mexico, Netherlands, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04896008. Randomized; triple masking; primary purpose treatment. Start 2021-12-01 (actual); primary completion 2024-07-26 (actual). Results posted on 2025-08-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
- Acronym
- ZENITH
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Sotatercept
- Intervention (Other)
- Placebo
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Record details
- Record id
cardio:ct-nct04896008- Content hash
3d56028400919e0115ea97cb4650433dfdb3e792d5f146befe7aeae579cf021e